Ontology highlight
ABSTRACT: Purpose
While immune checkpoint blockade (ICB) has become a pillar of cancer treatment, biomarkers that consistently predict patient response remain elusive due to the complex mechanisms driving immune response to tumors. We hypothesized that a multi-dimensional approach modeling both tumor and immune-related molecular mechanisms would better predict ICB response than simpler mutation-focused biomarkers, such as tumor mutational burden (TMB).Experimental design
Tumors from a cohort of patients with late-stage melanoma (n = 51) were profiled using an immune-enhanced exome and transcriptome platform. We demonstrate increasing predictive power with deeper modeling of neoantigens and immune-related resistance mechanisms to ICB.Results
Our neoantigen burden score,
SUBMITTER: Abbott CW
PROVIDER: S-EPMC9401549 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature